CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride and what is the scope of freedom to operate?

Chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride has thirty-four patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

International Patents:	34
US Patents:	1
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Constraining patent/regulatory exclusivity:

7,863,287

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Drug Class	Histamine-1 Receptor Antagonist Nonsteroidal Anti-inflammatory Drug alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Cyclooxygenase Inhibitors Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

C01EB	Other cardiac preparations
C01E	OTHER CARDIAC PREPARATIONS
C01	CARDIAC THERAPY
C	Cardiovascular system

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

G02CC	Antiinflammatory products for vaginal administration
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

M01AE	Propionic acid derivatives
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

R02AX	Other throat preparations
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

R03CA	Alpha- and beta-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R06AB	Substituted alkylamines
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	CHILDREN'S ADVIL ALLERGY SINUS	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	SUSPENSION;ORAL	021587-001	Feb 24, 2004		OTC	Yes	Yes
Haleon Us Holdings	ADVIL ALLERGY SINUS	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	TABLET;ORAL	021441-001	Dec 19, 2002		OTC	Yes	Yes	7,863,287		Y

Expired US Patents for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	CHILDREN'S ADVIL ALLERGY SINUS	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	SUSPENSION;ORAL	021587-001	Feb 24, 2004	10,238,640

International Patents for CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004056320
Peru	20081072	COMPOSICIONES DE ANTI-HISTAMINICOS, DESCONGESTIVOS, ANTITUSIVOS Y DROGAS ANTI-INFLAMATORIOS NO ESTEROIDALES
Russian Federation	2322262	КОМПОЗИЦИИ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ПРОТИВОЗАСТОЙНЫХ СРЕДСТВ И АНТИГИСТАМИНОВ (COMPOSITIONS OF NONSTEROID ANTI-INFLAMMATORY DRUGS, ANTICONGESTIVE AGENTS AND ANTIHISTAMINICS)

Market Dynamics and Financial Trajectory for Chlorpheniramine Maleate, Ibuprofen, and Pseudoephedrine Hydrochloride

Last updated: February 20, 2026

This analysis reviews the current market environment, regulatory landscape, sales trends, and future growth projections for chlorpheniramine maleate, ibuprofen, and pseudoephedrine hydrochloride.

What Are the Market Sizes and Growth Rates?

Drug	Global Market Size (2022)	CAGR (2023-2028)	Key Drivers
Chlorpheniramine Maleate	$1.1 billion	4.1%	High OTC availability; broad antihistamine demand
Ibuprofen	$6.2 billion	4.3%	Widely used NSAID; OTC dominance
Pseudoephedrine Hydrochloride	$1.05 billion	3.8%	Restricted sale due to regulatory controls; demand for decongestants

Sources: MarketsandMarkets, Grand View Research (2023 estimates).

How Are Regulatory Policies Impacting the Market?

Chlorpheniramine Maleate

• OTC status varies globally; in the U.S., it remains OTC.
• Some countries impose sales limitations due to sedative properties.
• Regulatory scrutiny around side effects influences formulation approvals.

Ibuprofen

• Approved globally with consistent dosing guidelines.
• Some markets, such as Canada and Europe, regulate high-dose sales.
• Recent policies emphasize labeling improvements; no major restrictions.

Pseudoephedrine Hydrochloride

• Subject to tight controls under the Combat Methamphetamine Epidemic Act in the U.S.
• Sales limited to pharmacy settings; record-keeping required.
• International regulations vary, impacting supply chains.

What Are the Key Market Trends?

Over-the-Counter (OTC) Versus Prescription

• Ibuprofen remains predominantly OTC, facilitating widespread consumer access.
• Chlorpheniramine maleate is OTC, but certain formulations are prescription-only in select markets.
• Pseudoephedrine is mainly OTC but heavily regulated, affecting volume.

Innovation and Formulation Trends

• Development of combination products (e.g., antihistamine-decongestant combos).
• Introduction of sustained-release formulations for pseudoephedrine.
• Shift towards non-sedating antihistamines limits chlorpheniramine use.

Distribution Channels

• Online sales are expanding but face regulatory hurdles, especially for pseudoephedrine.
• Pharmacies and supermarkets remain primary channels.

How Do Sales Trends Compare Historically and Recently?

Year	Chlorpheniramine Maleate	Ibuprofen	Pseudoephedrine HCl
2018	$950 million	$5.7 billion	$950 million
2022	$1.1 billion	$6.2 billion	$1.05 billion
2023 p	+3.6%	+4.4%	+4.2%

Projection based on quarterly sales reports.

Growth translations include rising demand in emerging markets, despite regulatory restrictions for pseudoephedrine.

What Are Future Growth Drivers and Risks?

Growth Drivers

• Expansion into emerging markets with rising health awareness.
• Increasing consumer preference for OTC products.
• Continual reformulation to improve safety profiles.

Risks

• Regulatory tightening, especially for pseudoephedrine.
• Supply chain disruptions, notably in raw materials like ephedrine.
• Competition from new pharmacological alternatives.

What Are Competitive Landscape and Patent Trends?

Patent Status

• Many patents for pseudoephedrine formulations expired in the last five years.
• Chlorpheniramine maleate patents have largely expired; generic manufacturers dominate.
• Ibuprofen patents expired decades ago; no significant patent protections remain.

Key Players

• Pfizer, Johnson & Johnson, and Teva lead in OTC formulations.
• Regional brands in Asia and Europe capture significant market share.

Financial Outlook Summary

Metric	2023 Estimate	2028 Projection	Notes
Market Size	$8.35 billion	$10.6 billion	Compound growth rate (CAGR): ~4.2%
Profit Margins	15-20%	Stable	OTC products benefit from high volume but pressure on margins from generics

Closing Analysis

The combined market for chlorpheniramine maleate, ibuprofen, and pseudoephedrine hydrochloride remains stable with moderate growth, driven primarily by OTC demand and expanding markets. Regulatory trends, especially for pseudoephedrine, will influence market access and sales volume. Innovation in formulations and the digitalization of sales channels are expected to shape competitive strategies.

Key Takeaways

• The overall market size is expected to grow approximately 4.2% annually through 2028.
• Ibuprofen maintains dominant market share owing to widespread use and consistent regulatory status.
• Pseudoephedrine hydrochloride faces ongoing regulatory limitations, impacting supply chain and sales.
• Patent expiries have opened markets to generic manufacturers; brand differentiation relies on formulations and marketing.
• Emerging markets could become significant growth drivers over the next five years.

Frequently Asked Questions

1. How does regulation affect pseudoephedrine sales?

Regulations limit pseudoephedrine sales through record-keeping, purchase limits, and sales in licensed facilities. These rules vary by country but generally restrict OTC sales, reducing volume and impacting revenue.

2. What are the main market opportunities for new formulations?

Developing non-sedating antihistamines, sustained-release decongestants, and combination OTC products can capture consumer interest and expand market share.

3. Which competitors lead in this market?

Pfizer, Johnson & Johnson, and Teva dominate OTC markets through established brands. Regional players in Asia and Europe are also significant.

4. How does e-commerce influence this market?

Online sales have increased but face regulation, particularly for pseudoephedrine. Companies investing in digital channels target consumer convenience and expand reach.

5. What are the key risks for market growth?

Regulatory tightening, raw material supply disruptions, and increasing generic competition threaten growth prospects. Strategic planning must consider these factors.

---

References

[1] MarketsandMarkets. (2023). OTC Pharmaceuticals Market Report. Retrieved from https://www.marketsandmarkets.com

[2] Grand View Research. (2023). Over-the-Counter (OTC) Drugs Market Size, Share & Trends. Retrieved from https://www.grandviewresearch.com